Accueil   Diary - News   All news Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2021

Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2021

 

  • WYMEEG® (Imeglimin hydrochloride) launched in Japan on September 16 for the treatment of type 2 diabetes
  • Milestone payment for TWYMEEG’s approval in Japan of JPY 1.75 billion (approximately EUR 13.2 million, USD 15.8 million)1 paid by Sumitomo Dainippon Pharma to Poxel in July 2021
  • Patient enrollment in PXL065 Phase 2 (DESTINY-1) trial in NASH completed in September with results expected in Q3 2022
  • Phase 2a clinical Proof of Concept (POC) biomarker studies of PXL065 and PXL770 in X-linked adrenoleukodystrophy (ALD) planned to initiate in early 2022 with data expected by year end 2022
  • As of September 30, 2021, cash and cash equivalents were EUR 37.2 million (USD 43.2 million)

 

 

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2021.

 

 

Read the press release